OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis

Roche announced today that new OCREVUS ® (ocrelizumab) data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) from 10 October to 12 October in Berlin, Germany. (Source: Roche Media News)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read full article on medworm.com


Follow Us on Twitter

Follow Us On Twitter - Image